Loading…
Researchers led by Dr. Asis Bala of the Institute of Advanced Study in Science and Technology (IASST), Guwahati — an autonomous institute of the Department of Science & Technology — and Dr. K.P. Bhabak of IIT Guwahati have developed a 'smart' anticancer molecule named RK-251.
RK-251 stays inactive as it travels through the body and is switched on by the abnormally high levels of reactive oxygen species (ROS) inside cancer cells, where it releases the anticancer compound NBDHEX; NBDHEX blocks target proteins that cancer cells use to survive and resist treatment.
In preclinical work the molecule showed strong activity against aggressive triple-negative breast cancer cells with much less effect on healthy cells, and no obvious toxicity in zebrafish (Danio rerio) embryos; the work is published in the ACS Journal of Medicinal Chemistry and further studies are needed before human testing.
A prodrug is a chemically masked, biologically inactive form of a medicine. It circulates harmlessly until some condition specific to the target tissue removes the mask and liberates the active drug. RK-251 uses reactive oxygen species (ROS) as that condition. ROS are chemically aggressive oxygen-containing molecules produced during normal cell metabolism; cancer cells, because of their distorted metabolism, generate them at far higher levels than normal cells. A chemical group that is cleaved by ROS therefore behaves as a lock that only tumour cells can pick. When the lock opens inside the cancer cell, RK-251 releases NBDHEX, a nitrobenzoxadiazole-based inhibitor of the enzyme glutathione transferase P1-1 (GSTP1-1) — an enzyme tumour cells lean on to detoxify drugs and to keep survival signalling alive. The same chemistry also makes the molecule fluoresce when ROS is present, which is how the researchers could see activation in the zebrafish embryos.
Simple Analogy: Conventional chemotherapy is a weedkiller sprayed over the whole garden — it kills the weeds and scorches the flowers. A ROS-activated prodrug is a capsule of weedkiller that only dissolves in the peculiar soil chemistry under a weed.
| Aspect | Chemotherapy | Targeted therapy | Immunotherapy |
|---|---|---|---|
| What it attacks | Any rapidly dividing cell in the body | A specific molecule, protein or pathway the cancer cell depends on | The patient's own immune system, which is then unleashed on the tumour |
| Selectivity | Low — healthy fast-dividing tissue (bone marrow, gut lining, hair follicles) is hit too | High — needs the target to be present in that tumour | Indirect — acts on immune checkpoints rather than on the tumour cell |
| Typical limitation | Adverse effects on healthy cells; resistance | Works only if the tumour carries the target; resistance by mutation | Response varies widely between patients; immune-related adverse effects |
| Where RK-251 fits | It is intended as a replacement for untargeted chemotherapy | It is a targeted approach — the ROS trigger plus GSTP1-1 inhibition | Not applicable |
Set up in 1979 by the Assam Science Society to build a premier research establishment for the North East; inaugurated on 3 November 1979 by Nobel laureate Prof. Dorothy Hodgkin. Taken over by the Ministry of Science and Technology in March 2009 as one of its autonomous R&D institutes; it now functions under the Department of Science & Technology. Led the RK-251 research.
The nodal department of the Ministry of Science and Technology for promoting new areas of science and technology. It administers 24 autonomous institutes — 15 R&D institutes, 2 service organisations, 4 professional bodies/science academies and 3 statutory bodies — IASST among them.
Partner institution; Dr. K.P. Bhabak co-led the chemistry of the molecule. IIT Guwahati is an Institute of National Importance under the Ministry of Education.
India's flagship cancer hospital and research centre, functioning under the Department of Atomic Energy. It coordinates the National Cancer Grid.
Launched in 2012 and coordinated by the Tata Memorial Centre, it is a network of cancer centres, research organisations and patient groups created to bring uniform standards to cancer prevention, diagnosis and treatment, to run specialised training and to enable collaborative research. A Government reply in 2026 put the network at 380 cancer centres, research organisations and patient groups.
TNBC is breast cancer whose cells lack oestrogen and progesterone receptors and do not over-express HER2. Because the three receptors that hormone therapy and HER2-targeted drugs act on are absent, chemotherapy has been the main systemic option — which is exactly why a selective, ROS-activated molecule is being tested against it. TNBC accounts for roughly 15% of invasive breast cancers.
Danio rerio embryos are transparent, develop outside the mother and grow fast, so a fluorescent compound can literally be watched working inside a living animal. This is why zebrafish sit between cell-culture work and mammalian trials in the preclinical pipeline.
IASST is the DST's principal research anchor in the North East, created explicitly to work on the region's problems. Research output of this kind is the counter-argument to the perception that frontier science in India is confined to the metros.
GS Paper 3 > Science and Technology > Developments in Biotechnology and their applications
General Awareness > Science and Technology in the News
General Awareness > Science and Technology
Institution-to-department pairings and 'new molecule/technology developed by an Indian institute' bytes appear every year in SSC and railway General Awareness, and periodically in UPSC Prelims science questions.
An inactive form of a medicine that is converted into the active drug only after it meets a specific chemical or enzymatic trigger in the body.
Chemically reactive oxygen-containing molecules produced during cell metabolism; cancer cells characteristically carry much higher levels than healthy cells.
A nitrobenzoxadiazole-based inhibitor of the enzyme glutathione transferase P1-1; the anticancer compound RK-251 releases inside the tumour cell.
Breast cancer lacking oestrogen and progesterone receptors and without HER2 over-expression, so hormone and HER2-targeted therapies do not work on it.
The zebrafish — a small freshwater fish widely used as a vertebrate model organism in preclinical toxicity and imaging studies.